13D Filing: Adage Capital Management and Inotek Pharmaceuticals Corp (ITEK)

Item 2.

IDENTITY AND BACKGROUND

(a)

This statement is filed by:

(i)

Adage Capital Partners, L.P., a Delaware limited partnership (“ACP“) with respect to the shares of Common Stock directly owned by it;

(ii)

Adage Capital Partners GP, L.L.C., a limited liability company organized under the laws of the State of Delaware (“ACPGP“), as general partner of ACP with respect to the shares of Common Stock directly owned by ACP;

(iii)

Adage Capital Advisors, L.L.C., a limited liability company organized under the laws of the State of Delaware (“ACA“), as managing member of ACPGP, general partner of ACP, with respect to the shares of Common Stock directly owned by ACP;

(iv)

Robert Atchinson (“Mr. Atchinson“), as managing member of ACA, managing member of ACPGP, general partner of ACP with respect to the shares of Common Stock directly owned by ACP; and

(v)

Phillip Gross (“Mr. Gross“), as managing member of ACA, managing member of ACPGP, general partner of ACP with respect to the shares of Common Stock directly owned by ACP.

The foregoing persons are hereinafter sometimes collectively referred to as the “Reporting Persons.” Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party.

The filing of this statement should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of the securities reported herein.

(b)

The address of the business office of each of the Reporting Persons is 200 Clarendon Street, 52nd floor, Boston, Massachusetts 02116.

13D Filing: Adage Capital Management and Inotek Pharmaceuticals Corp (ITEK)

Published on October 5, 2017 at 2:20 pm by Insider Monkey Staff in Hedge Funds

Page 7 of 13 – SEC Filing

Follow Rocket Pharmaceuticals Inc. (NASDAQ:RCKT)

Follow Rocket Pharmaceuticals Inc. (NASDAQ:RCKT)

AI Fire Sale: Insider Monkey’s #1 AI Stock Pick Is On A Steep Discount

Published on October 30, 2024 at by Inan Dogan, PhD

A New Dawn is Coming to U.S. Stocks

Published on November 16, 2024 at by Insider Monkey Staff

Item 1.	SECURITY AND ISSUER

	This statement on Schedule 13D (the “Schedule 13D“) relates to the Common Stock, $0.01 par value per share (the “Common Stock“), of Inotek Pharmaceuticals Corporation, a Delaware corporation (the “Issuer“). The Issuer’s principal executive offices are located at 91 Hartwell Avenue, Lexington, Massachusetts 02421.